MedTrace Logo

Estrogen Pretreatment Prior to GnRH Antagonist Protocol

NCT01489852 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 472

Last updated 2011-12-12

No results posted yet for this study

Summary

The purpose of this study is to assess whether estrogen pre-treatment can allow retrieval of 2 additional oocytes in GnRH antagonist protocol.

Conditions

Interventions

DRUG

17beta-estradiol

Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.

Sponsors & Collaborators

  • Gemer

    lead OTHER

Principal Investigators

  • Jean Noel Hugues, MD, PhD · Hôpital Jean Verdier

  • Isabelle cedrin-durnerin, MD · Hôpital Jean Verdier

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-12-31
Primary Completion
2010-07-31
Completion
2011-05-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01489852 on ClinicalTrials.gov